Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 7/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.54 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.38 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 3/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1107642 | 0.94 | GCK (0.52) | GCKKCNH2P2RX3P2RX2MAPK1 | |
| SCHEMBL1107616 | 0.94 | GCK (0.52) | GCKKCNH2P2RX3P2RX2MAPK1 | |
| SCHEMBL1107612 | 0.90 | GCK (0.53) | GCKKCNH2P2RX3P2RX2MAPK1 | |
| SCHEMBL1107692 | 0.88 | GCK (0.51) | GCKKCNH2P2RX3P2RX2MAPK1 | |
| SCHEMBL1107649 | 0.88 | GCK (0.51) | GCKKCNH2P2RX3P2RX2MAPK1 | |
| SCHEMBL1107624 | 0.87 | GCK (0.48) | GCKKCNH2P2RX3P2RX2ACACB | |
| SCHEMBL1107529 | 0.87 | GCK (0.48) | GCKKCNH2P2RX3P2RX2ACACB | |
| SCHEMBL1107621 | 0.84 | GCK (0.52) | GCKKCNH2P2RX3P2RX2MAPK1 | |
| SCHEMBL1107613 | 0.83 | GCK (0.49) | GCKKCNH2P2RX3P2RX2MAPK1 | |
| SCHEMBL1107530 | 0.82 | GCK (0.55) | GCKKCNH2MAPK1HTTGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2012-06-07 | — | — | US | disclosed |
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, GCK, PCK1 | GCK 2/4885KCNH2 634/4885P2RX3 1324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.